TURBO OPTIONSSCHEIN - VIVORYON THERAPEUTICS | Real-time Bid/Ask 08:59:51 2024-05-27 EDT | ||
| 3.12 EUR / 3.18 EUR | +194.39% |
|
| Current month | +91.07% | ||
| 1 month | +101.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VIVORYON THERAPEUTICS N.V.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 3.05 | +185.05% |
| 24-05-24 | 1.07 | +32.10% |
| 24-05-23 | 0.81 | +32.79% |
| 24-05-22 | 0.61 | -3.17% |
| 24-05-21 | 0.63 | +1.61% |
Delayed Quote Börse Stuttgart
Last update May 27, 2024 at 06:38 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VIVORYON THERAPEUTICS N.V. |
| Issuer | Lang & Schwarz |
| WKN | LX3Y68 |
| ISIN | DE000LX3Y680 |
| Date issued | 2024-03-06 |
| Strike | 0.2 € |
| Maturity | 2024-12-12 (199 Days) |
| Parity | 1 : 1 |
| Emission price | 0.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.05 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.06 € |
| Spread % | 1.89% |
Company Profile
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Sector
-
Consensus: Vivoryon Therapeutics N.V.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.11
EUR
Average target price
41.57
EUR
Spread / Average Target
+1,869.98%
- Stock Market
- Certificates
- Certificat
